Using SYLOID® Mesoporous Silica As An Additive To Mitigate Powder Flow And Static Issues In Micronization Processes

In this experiment, Acetaminophen and Ibuprofen were chosen as model compounds to evaluate how micronization affects powder flow characteristics and how these properties can be improved through the incorporation of varying levels of SYLOID® 244 FP mesoporous silica. By examining flow behavior before and after micronization, the study provided valuable insights into how small additive adjustments can influence the handling, uniformity, and performance of active pharmaceutical ingredients.

The findings revealed that even minimal additions of mesoporous silica can markedly enhance the physical properties of micronized APIs, resulting in smoother downstream blending and more consistent formulation outcomes.

Explore the full study to see how optimizing particle behavior can elevate process efficiency and product quality.